



Immuno-Oncology Summit 2017

Centre de Recherche des Cordeliers (CRC) – Paris

July 6, 2017

Morning session – Amphithéâtre Farabeuf

- 08:00 a.m. Welcome**
- 08:20 a.m. Synergy between radiotherapy and immunotherapy**
Silvia Chiara Formenti, M.D.,
Weill Cornell Medicine, New York, USA
- 08:45 a.m. Melanoma: immunotherapy in advanced melanoma and in the adjuvant setting**
Alexander Eggermont, M.D., Ph.D., Gustave
Roussy Cancer Center, Villejuif, France
- 09:10 a.m. Immune checkpoint inhibition in lung cancer**
Roy S. Herbst, M.D.,
Yale University, New Haven, USA
- 09:35 a.m. Predictors of response to immune checkpoint blockade**
Jennifer Wargo, M.D., Ph.D.,
MD Anderson Cancer Center, Houston, USA
- 10:00 a.m. Case study and open discussion**
- 10:20 a.m. Coffee break**
- 10:40 a.m. NK cell-based therapy**
Eric Vivier, Vet, Ph.D., Center of Immunology
Marseille-Luminy, France
- 11:05 a.m. Immunotherapy of gliomas**
Michael Platten, M.D., Ph.D., German Cancer
Research Center (DKFZ), Heidelberg, Germany
- 11:30 a.m. PDL-1 and other immunological diagnosis tools**
Janis M. Taube, M.D., Ph.D.,
Johns Hopkins University School
of Medicine, Baltimore, USA
- 11:55 a.m. Case study and open discussion**
- 12:15 p.m. Lunch break**

Morning session – Amphithéâtre Bilsky-Pasquier

- 08:00 a.m. Welcome**
- 08:20 a.m. Challenges in colorectal cancer: from vaccines to macrophage repolarization**
Niels Halama, M.D., German Cancer Research
Center (DKFZ), Heidelberg, Germany
- 08:45 a.m. Immune therapies in phase 1 trials**
Jean-Charles Soria, M.D., Ph.D., Gustave
Roussy Cancer Center, Villejuif, France
- 09:10 a.m. Oncolytic viruses: T VEC and others**
Igor Puzanov, M.D., Roswell Park Cancer
Institute, Buffalo, USA
- 09:35 a.m. Cancer vaccines in HPV malignancies**
Cornelia Trimble, M.D., Ph.D., Johns Hopkins
Outpatient Center, Baltimore, USA
- 10:00 a.m. Case study and open discussion**
- 10:20 a.m. Coffee break**
- 10:40 a.m. Co-stimulation agonists via CD137, OX40, GITR and CD27 for immunotherapy of cancer**
Ignacio Melero, M.D., Ph.D., Center for
Applied Medical Research (CIMA),
University of Navarra, Pamplona, Spain
- 11:05 a.m. Assessing T cell receptor affinity and avidity against tumor antigens**
Mathilde Allard, Ph.D.,
University of Lausanne, Switzerland
- 11:30 a.m. PD1 checkpoint blockade in melanoma: from monotherapy to combination therapies**
Dirk Schadendorf, M.D.,
University of Essen, Germany
- 11:55 a.m. Case study and open discussion**
- 12:15 p.m. Lunch break**

This program is supported by independent educational grants from Miltenyi Biotec GmbH, Incyte Corporation, Servier, Lytix Biopharma AS, and the European Academy of Tumor Immunology. Jointly provided by Postgraduate Institute for Medicine and KC Consulting.

Target audience: This activity is targeted to medical oncologists/hematologist-oncologists who actively manage, treat and follow-up with patients with various malignancies being treated with immuno-oncology anticancer agents, including combination cancer immunotherapies (CCIT).

Accreditation statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and KC Consulting, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

July 6, 2017

Afternoon session –
Amphithéâtre Farabeuf

- 01:30 p.m. Regulatory T cells: their role, mechanism of action, and impact on cancer**
Dario Vignali, Ph.D.,
University of Pittsburgh, USA
- 01:55 p.m. CD8⁺ T cells in immunotherapy, radiotherapy, and chemotherapy**
Weiping Zou, M.D., Ph.D.,
University of Michigan, Ann Arbor, USA
- 02:20 p.m. Purinergic receptors: novel targets for cancer immunotherapy**
Michèle Teng, Ph.D.,
QIMR Berghofer Medical Research Institute,
Brisbane, Australia
- 02:55 p.m. Biology of myeloid-derived suppressor cells**
Dmitry I. Gabrilovich, M.D., Ph.D.,
The Wistar Institute, Philadelphia, USA
- 03:20 p.m. Coffee break**
- 03:40 p.m. The impact of the intestinal microbiota in therapeutic responses against cancer**
Laurence Zitvogel, M.D., Ph.D.,
Gustave Roussy Cancer Center,
Villejuif, France
- 04:05 p.m. Side effects of immunotherapy with checkpoint inhibitors**
Paolo Ascierto, M.D., Ph.D.,
National Tumor Institute, Napoli, Italy
- 04:30 p.m. Case study and open discussion**
- 05:00 p.m. End of session**

Afternoon session –
Amphithéâtre Bilsky-Pasquier

- 01:30 p.m. Tumor-targeted antibodies**
Aurélien Marabelle, M.D., Ph.D.,
Gustave Roussy Cancer Center,
Villejuif, France
- 01:55 p.m. Plasmacytoid DC/Regulatory T cell interactions at the center of an immunosuppressive network in breast and ovarian tumors**
Christophe Caux, Ph.D.,
Centre Léon Bérard, Lyon, France
- 02:20 p.m. Mutant epitopes in cancer***
Markus Maeurer, M.D., Ph.D.,
Karolinska Institute, Stockholm, Sweden
- 02:55 p.m. PD1 blockade in renal cell carcinoma***
Lisa Derosa, M.D.,
Gustave Roussy Cancer Center,
Villejuif, France
- 03:20 p.m. Coffee break**
- 03:40 p.m. Immune monitoring of blood and tumor microenvironment**
Daniel Speiser, Ph.D.,
University of Lausanne, Switzerland
- 04:05 p.m. Case study and open discussion**
- 04:35 p.m. End of session**

*CME credit will not be offered for this presentation.



For more information, please visit <https://tinyurl.com/k3ausgk>

This program is supported by independent educational grants from Miltenyi Biotec GmbH, Incyte Corporation, Servier, Lytix Biopharma AS, and the European Academy of Tumor Immunology. Jointly provided by Postgraduate Institute for Medicine and KC Consulting.
Target audience: This activity is targeted to medical oncologists/hematologist-oncologists who actively manage, treat and follow-up with patients with various malignancies being treated with immuno-oncology anticancer agents, including combination cancer immunotherapies (CCIT).
Accreditation statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and KC Consulting, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

July 7, 2017

Morning session –
Amphithéâtre Farabeuf

- 08:00 a.m. Welcome**
- 08:20 a.m. Innate immune receptors in the regulation of tumor immunity**
Tadatsugu Taniguchi, Ph.D.,
University of Tokyo, Japan
- 08:45 a.m. Peptide-based therapeutic cancer vaccines***
Cornelis Melief, M.D., Ph.D.,
Leiden University Medical Center,
The Netherlands
- 09:10 a.m. Immunotherapy for prostate cancer: An evolving landscape**
Charles Drake, M.D., Ph.D.,
Columbia University Medical Center,
New York, USA
- 09:35 a.m. Cancer immunosurveillance by natural killer cells and other innate lymphoid cells**
Mark J. Smyth, Ph.D.,
QIMR Berghofer Medical Research Institute,
Brisbane, Australia
- 10:00 a.m. Current status of onco-immunology in hematologic cancers**
David Ghez, M.D., and Bertrand Routy, M.D.,
Gustave Roussy Cancer Center,
Villejuif, France
- 10:25 a.m. Coffee break**
- 10:45 a.m. Local immunotherapies of cancer**
Joshua Brody, M.D., Ph.D.,
Icahn School of Medicine at Mount Sinai,
New York, USA
- 11:10 a.m. IDO- and TDO-based inhibition in cancer**
George Prendergast, M.D., Ph.D.,
Lankenau Institute for Medical Research,
Philadelphia, USA
- 11:35 a.m. Case study and open discussion**
- 12:00 p.m. End of session**
- 12:20 p.m. Lunch break**

*CME credit will not be offered for this presentation.

Morning session –
Amphithéâtre Bilsky-Pasquier

- 08:00 a.m. Welcome**
- 08:20 a.m. The human tumor microenvironment**
Wolf Herman Fridman, M.D., Ph.D.,
and Catherine Sautès Fridman, M.D., Ph.D.,
Cordeliers Research Center, Paris, France
- 08:45 a.m. The secrets of T cell polarization**
Lionel Apetoh, Ph.D.,
INSERM, Centre Georges-François Leclerc,
University of Dijon, France
- 09:10 a.m. Immunogenic stress and death of cancer cells in natural and therapy-induced immunosurveillance**
Guido Kroemer, M.D., Ph.D.,
Gustave Roussy Cancer Center,
Villejuif, France
- 09:35 a.m. Effect of pharmaceutical compounds on myeloid-derived suppressor cells (MDSCs)**
François Ghiringhelli, M.D., Ph.D.,
INSERM, Centre Georges-François Leclerc,
University of Dijon, France
- 10:00 a.m. Resident memory T cells play a key role in the efficacy of cancer vaccines**
Eric Tartour, M.D., Ph.D.,
Hôpital Européen Georges Pompidou,
Paris, France
- 10:25 a.m. Coffee break**
- 10:45 a.m. Challenges of onco-immunology for breast and ovarian cancers**
Emmanuela Romano, M.D., Ph.D.,
Institut Curie Research Center, Paris, France
- 11:10 a.m. BCG and Anti-PDL-1 Ab in bladder cancers**
Yohann Loriot, M.D.,
Gustave Roussy Cancer Center,
Villejuif, France
- 11:35 a.m. Case study and open discussion**
- 12:00 p.m. Concluding remarks**
Wolf Herman Fridman, M.D., Ph.D.,
Cordeliers Research Center, Paris, France
and Pedro Romero, M.D., Université de
Lausanne, Switzerland
- 12:20 p.m. Lunch break**



For more information, please visit <https://tinyurl.com/k3ausgk>

This program is supported by independent educational grants from Miltenyi Biotec GmbH, Incyte Corporation, Servier, Lytix Biopharma AS, and the European Academy of Tumor Immunology. Jointly provided by Postgraduate Institute for Medicine and KC Consulting.
Target audience: This activity is targeted to medical oncologists/hematologist-oncologists who actively manage, treat and follow-up with patients with various malignancies being treated with immuno-oncology anticancer agents, including combination cancer immunotherapies (CCIT).
Accreditation statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and KC Consulting, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

July 7, 2017

Afternoon session** – Amphithéâtre Farabeuf

Landscape of immuno-oncology in the next 5 years

Please join us for a special series of presentations from leading experts in academia and industry to explore the challenges and opportunities ahead in the exciting field of immuno-oncology.

As these presentations will feature speakers from industry, continuing medical education credit will not be provided.

- | | | | |
|-------------------|---|-------------------|---|
| 01:30 p.m. | Welcome
Guido Kroemer, M.D., Ph.D.,
Gustave Roussy Cancer Center,
Villejuif, France | 03:40 p.m. | Active immunization using a novel heteroclitic peptide mixture against WT1 (galinpepimut-S): Preliminary evidence of multifunctional cross-epitope T-cell reactivity and summary of clinical research efforts
Nicholas J. Sarlis, M.D., Ph.D.,
Sellas Life Sciences Group, New York, USA |
| 01:40 p.m. | The mechanistic basis of anti-PD-L1/PD-1-based immunotherapy
Ira Mellman, Ph.D.,
Genentech, South San Francisco, USA | 04:05 p.m. | Enabling CAR T cell therapy through closed-system manufacturing
Andrew Kaiser, Ph.D.,
Miltenyi Biotec, Bergisch Gladbach,
Germany |
| 02:05 p.m. | Mechanisms of protective immunotherapy
Glenn Dranoff, M.D.,
Novartis, Cambridge, USA | 04:30 p.m. | Concluding remarks and awards ceremony
Guido Kroemer, M.D., Ph.D.,
Gustave Roussy Cancer Center,
Villejuif, France
Laurence Zitvogel, M.D., Ph.D.,
Gustave Roussy Cancer Center,
Villejuif, France |
| 02:30 p.m. | Integration of science and technology innovation: a modular approach to oncology cell therapy
Cedrik Britten, M.D.,
GlaxoSmithKline (GSK), Stevenage, UK | | |
| 02:55 p.m. | Coffee break | | |
| 03:15 p.m. | Cancer immunotherapy: What's on the horizon for patients?
John C. Reed, M.D., Ph.D.,
Roche, Basel, Switzerland | | |

This program is supported by GlaxoSmithKline and an anonymous donation.

**The July 7 afternoon session of the meeting is not supported by educational grants and CME credit will not be provided.



For more information, please visit <https://tinyurl.com/k3ausgk>

This program is supported by independent educational grants from Miltenyi Biotec GmbH, Incyte Corporation, Servier, Lytix Biopharma AS, and the European Academy of Tumor Immunology. Jointly provided by Postgraduate Institute for Medicine and KC Consulting.
Target audience: This activity is targeted to medical oncologists/hematologist-oncologists who actively manage, treat and follow-up with patients with various malignancies being treated with immuno-oncology anticancer agents, including combination cancer immunotherapies (CCIT).
Accreditation statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and KC Consulting, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.